Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in HTLV-1-associated Myelopathy
NCT04004819Phase 2Unknown
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Aug 2019
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab in HTLV-1-associated myelopathy (HAM) (2 arms), sponsored by The First Hospital of Fujian Medical University. Primary endpoint: Expanded Disability Status Scale at 12 months. Status: unknown.
02
Drugs
rituximab
03
Conditions
HTLV-1-associated myelopathy (HAM)
Beyond the preview
Go deeper on NCT04004819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04004819.